Physical Evaluations of Patients with Premature Ventricular ComplexPhysical Evaluations of Healthy Individuals
Physical Evaluations of Patients with Premature Ventricular Complex: In this study, data from individuals with premature ventricular complex will be collected through face-to-face assessments. Respiratory functions, respiratory and peripheral muscle strength, cough strength, physical activity level, and quality of life will be assessed in these individuals who meet the inclusion criteria. All data obtained through these assessments will be collected from participants face-to-face at one time and for a maximum of approximately 1 hour.
Physical Evaluations of Healthy Individuals: In this study, data from healthy individuals will be collected through face-to-face assessments. Respiratory functions, respiratory and peripheral muscle strength, cough strength, physical activity level, and quality of life will be assessed in these individuals who meet the inclusion criteria.All data obtained through these assessments will be collected from participants face-to-face at one time and for a maximum of approximately 1 hour.
Study summary
Premature ventricular complexes may be observed in individuals without underlying disease due to factors such as physical inactivity, advanced age, smoking, male sex, and psychosocial disturbances, and in some cases may result in sudden cardiac death. Therefore, the aim of this study is to investigate respiratory function, respiratory muscle strength, cough strength, handgrip strength, physical activity level, and quality of life in individuals with premature ventricular complexes.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria for Individuals with Premature Ventricular Complexes (PVCs):
* Aged between 18 and 80 years
* Presence of symptomatic premature ventricular complexes resistant to ≥1 antiarrhythmic medication (including β-blockers and calcium channel blockers)
* Premature ventricular complex burden ≥10%
* Ventricular arrhythmias originating from any focus within the right or left ventricle
* Physically able to participate in all study assessments
* Willingness to participate in the study by providing written informed consent
Inclusion Criteria for Control Group Participants:
* Aged between 18 and 80 years
* Healthy individuals
* Willingness to participate in the study
* Physically able to participate in all study assessments
Exclusion Criteria for Individuals with Premature Ventricular Complexes (PVCs):
* Left ventricular ejection fraction (LVEF) \<45% unless PVC-induced cardiomyopathy is documented (defined as a \>15% improvement in LVEF following reduction of PVC burden through pharmacological therapy or ablation)
* Progressive decline in LVEF within the last 4 months, regardless of etiology
* Severe heart failure classified as New York Heart Association (NYHA) Class ≥III
* Ventricular arrhythmias attributed to underlying structural heart disease, known myocardial scar, or myocarditis
* Change in the dosage of antiarrhythmic medications (including β-blockers and calcium channel blockers) within 2 months prior to enrollment
* Failed catheter ablation within 3 months prior to enrollment
* Known thyroid disorders or individuals undergoing renal dialysis
* Life expectancy \<12 months
* Presence of angina pectoris
* Diagnosis of chronic obstructive pulmonary disease (COPD) or asthma
* Resting heart rate \>120 beats/min
* Resting systolic blood pressure ≥180 mmHg
* Resting diastolic blood pressure ≥100 mmHg
* Resting peripheral oxygen saturation ≤90%
Exclusion Criteria for Control Group Participants:
* Presence of premature ventricular complexes
* Presence of any acute or chronic medical condition
Primary outcome measure(s)
Maximal inspiratory pressure (MIP) — through study completion, an average of 1 year The MIP which shows respiratory muscle strength will be evaluated using a portable mouth pressure measuring device based on American Thoracic Society and European Respiratory Society criteria.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.